BioCryst Strategic Shift
BioCryst Pharmaceuticals to Close Birmingham Discovery Center, Shifts to External R&D Focus
Key Points
ALPHA-ORBIT Phase 3 enrollment for navenibart has been completed, marking the largest pivotal HAE study to date.
ORLADEYO (berotralstat) manufacturing delay has been resolved and the oral pellets will be available in early August.
BioCryst updates 2026 non-GAAP operating expense guidance and reaffirmed revenue guidance as part of its shift to external innovation and disciplined capital allocation.
CEO Charlie Gayer describes the plan as leveraging a strong financial foundation to pursue a more agile, targeted external research approach to grow the rare-disease portfolio beyond current programs.
Valuation context shows BioCryst is near a $2.53 billion market cap, with GF Value around $12.75 implying about 21.8% undervaluation relative to a $9.97 stock price; forward P/E is elevated at 32.75 versus a 5-year median of 6.21.
BioCryst Pharmaceuticals is shutting its Birmingham Discovery Center of Excellence by the end of 2026 and ending all internal drug discovery programs, the company announced June 29. The move cuts $30 million from its 2026 operating expenses, reducing non-GAAP guidance to a range of $420 million to $440 million, according to Reuters.
CEO Charlie Gayer framed the decision as a strategic pivot, not a retreat. "A strong financial foundation" will let BioCryst pursue "a more agile, targeted external research approach," he said. The company will now rely on acquisitions and licensing deals — rather than internal labs — to build its rare-disease pipeline.
Birmingham Facility Closes After Four Decades of Research
BioCryst was founded in 1986 by academics from the University of Alabama at Birmingham (UAB) and the Southern Research Institute. For 40 years, the Birmingham hub was where the company developed its drugs from scratch using structure-guided design. The Board of Directors voted to close it on June 25, 2026, according to Fierce Biotech.
The closure is a significant blow to Birmingham's biotech community. Local outlets described BioCryst as the city's most successful homegrown pharma anchor. The company promised a "transition plan" for affected staff but has not released exact layoff numbers, Fierce Biotech reported.
Navenibart Trial Enrollment Completes as Pipeline Narrows to Two Bets
BioCryst's future now rests on two drugs. The first is navenibart, an HAE (hereditary angioedema) treatment acquired when BioCryst bought Astria Therapeutics in early 2026. Enrollment in the ALPHA-ORBIT Phase 3 trial is now complete — making it the largest pivotal HAE study ever run, according to MarketWatch. Top-line data is expected in Q3 2027.
The second is BCX17725, a KLK5 inhibitor for Netherton syndrome, a rare skin disease with no approved targeted therapy. Proof-of-concept data is expected by year-end 2026, according to Reuters. BioCryst also resolved a manufacturing delay for its existing drug ORLADEYO, with oral pellets for pediatric patients set to be available in early August.
Cost-Cutting Meets a Company Already Near Profitability
BioCryst reaffirmed its 2026 revenue guidance at $635 million to $660 million, with ORLADEYO expected to contribute $625 million to $645 million of that total, according to GuruFocus. The $30 million expense cut sharpens the company's path to sustainable profitability — a goal Gayer has made central to his tenure since taking the CEO role on January 1, 2026.
The stock trades around $9.97, giving BioCryst a market cap of roughly $2.53 billion. GuruFocus estimates the stock's fair value at $12.75, implying about 21.8% undervaluation, GuruFocus noted. Still, the forward price-to-earnings ratio sits at 32.75 — well above its five-year median of 6.21 — signaling investors are pricing in significant growth expectations.
Strategic Pivot Draws Praise and Skepticism in Equal Measure
Wall Street analysts largely view the move as "capital efficient," with resources now focused on the most advanced assets rather than early-stage lab work, according to GuruFocus. Insiders sold roughly $697,000 in stock over the past three months — a modest figure that analysts say signals no major loss of confidence from leadership.
But not everyone is convinced the model holds long term. Some biotech strategy observers warn that abandoning internal discovery leaves BioCryst fully dependent on the M&A market for future drug candidates, according to Mahoning Matters. Without an internal lab pipeline, every next-generation program will require a deal — and deals get expensive when competition for rare-disease assets heats up.
Sentiment
Mostly NegativePublishers
11
Articles
84
Reach
95
